Makoto Shinoto1, Shigeru Yamada2, Masahiko Okamoto3, Yoshiyuki Shioyama4, Tatsuya Ohno3, Takashi Nakano3, Kenji Nemoto5, Yuka Isozaki2, Shohei Kawashiro6, Hiroshi Tsuji2, Tadashi Kamada2. 1. Ion Beam Therapy Center, SAGA HIMAT Foundation, Tosu, Japan. Electronic address: shinoto@saga-himat.jp. 2. National Institutional of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan. 3. Department of Radiation Oncology, Gunma University, Graduate School of Medicine, Japan. 4. Ion Beam Therapy Center, SAGA HIMAT Foundation, Tosu, Japan. 5. Department of Radiation Oncology, Yamagata University, Faculty of Medicine, Japan. 6. National Institutional of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Radiation Oncology, Yamagata University, Faculty of Medicine, Japan.
Abstract
PURPOSE: We investigated the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally recurrent rectal cancer (LRRC). PATIENTS AND METHODS: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. RESULTS: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6-169 months). The OS rates were 73% (95% confidence interval [CI], 67%-79%) at 3 years and 51% (95%CI 44%-58%) at 5 years. The LC rates were 93% (95%CI 88%-96%) at 3 years, and 88% (95%CI 82%-93%) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity (n = 1) and pelvic infection (n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction (n = 2), gastrointestinal toxicity (n = 2), neuropathy (n = 1), and pelvic infection (n = 7). There was no grade 4 or 5 acute or late toxicity. CONCLUSIONS: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.
PURPOSE: We investigated the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally recurrent rectal cancer (LRRC). PATIENTS AND METHODS: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. RESULTS: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6-169 months). The OS rates were 73% (95% confidence interval [CI], 67%-79%) at 3 years and 51% (95%CI 44%-58%) at 5 years. The LC rates were 93% (95%CI 88%-96%) at 3 years, and 88% (95%CI 82%-93%) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity (n = 1) and pelvic infection (n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction (n = 2), gastrointestinal toxicity (n = 2), neuropathy (n = 1), and pelvic infection (n = 7). There was no grade 4 or 5 acute or late toxicity. CONCLUSIONS: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.
Authors: Timothy D Malouff; Laura A Vallow; Danushka Seneviratne; Anita Mahajan; Robert L Foote; Bradford Hoppe; Chris Beltran; Steven J Buskirk; Sunil Krishnan; Daniel M Trifiletti Journal: Int J Part Ther Date: 2020-11-05
Authors: Timothy D Malouff; Anita Mahajan; Sunil Krishnan; Chris Beltran; Danushka S Seneviratne; Daniel Michael Trifiletti Journal: Front Oncol Date: 2020-02-04 Impact factor: 5.738